The European Medicines Agency's CHMP has recommended approval for a new dosing schedule for Regeneron's cancer drug Libtayo (cemiplimab). The updated regimen allows patients to receive a higher dose (700 mg) every six weeks after an initial 12-week period of dosing every three weeks. Additionally, infusion times for the 350 mg dose may be shortened if the first dose is well tolerated, potentially reducing treatment time by half. This change aims to improve patient convenience across all approved cancer indications, with a final decision expected from the European Commission soon.
Regeneron Pharmaceuticals Inc (REGN) holds a market cap of $81.99 billion and an enterprise value of $76.70 billion as of Oct 16, 2026, 18:11 WIB. The stock price is USD 797.33, showing a modest 0.12% increase on the day. On Pluang, investor activity leans heavily toward selling, with 95% of orders to sell and only 5% to buy, while the typical holding period is 107 days.
